EXECUTIVE SECRETARY REPORT – JUNE, 2018

• FINANCIAL REPORT
  • 2018-2019 Budget

• TEMPORARY LICENSES

• STAFF ACTIVITIES
  • Sunset Committee (4/23) – Brett, Dave
  • Meetings with other health care boards – Dave, Paul, Brett
  • Governor's Task Force on Opiates (4/18) – Dave, Paul
  • NABP Annual Meeting (May) - staff
  • AB 474 meetings and continuing education - staff
  • CORA meeting (4/26) - Yenh

• REPORT TO BOARD
  • BD product information

• BOARD RELATED NEWS

• ACTIVITIES REPORT
<table>
<thead>
<tr>
<th>Regulation Number and Topic</th>
<th>Workshop Propose To Bd</th>
<th>30 Days To LCB W/Letter</th>
<th>LCB R0 Number Issued</th>
<th>LCB Return Date</th>
<th>30 Days Post Public Hearing</th>
<th>Public Hearing Meeting Date</th>
<th>To LCB Final W/ Cov./Info</th>
<th>Secretary of State File Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>639.955 Penalty for failing to transmit information required by NAC 639.926</td>
<td>03/02/16</td>
<td>03/11/16</td>
<td>R036-16</td>
<td>04/08/16</td>
<td>04/27/16</td>
<td>06/01/16</td>
<td>06/16/16</td>
<td>06/28/16</td>
</tr>
<tr>
<td>639.921 Sharing information between systems.</td>
<td>03/02/16</td>
<td>03/11/16</td>
<td>R035-16</td>
<td>04/08/16</td>
<td>06/15/16</td>
<td>07/20/16</td>
<td>Denied</td>
<td>07/21/16</td>
</tr>
<tr>
<td>453.NEW Naloxone</td>
<td>01/13/16</td>
<td>04/07/16</td>
<td>R058-16</td>
<td>05/04/16</td>
<td>06/15/16</td>
<td>07/20/16</td>
<td>08/05/16</td>
<td>09/09/16</td>
</tr>
<tr>
<td>639.7102 Use of computer system for issuance and transmission of prescription 639.7105 Electronic transmission of prescription</td>
<td>07/21/16</td>
<td>10/25/16</td>
<td>R154-16</td>
<td>07/05/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td>09/27/17</td>
<td>10/31/17</td>
</tr>
<tr>
<td>NAC 453.510 Schedule I add MAB-CHMINACA, AB-FUBINACA and ADB-PINACA</td>
<td>09/08/16</td>
<td>09/20/16</td>
<td>R151-16</td>
<td></td>
<td>Withdrawn – Duplicates R080-15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.540 Schedule IV add Eluxadoline</td>
<td>09/08/16</td>
<td>09/20/16</td>
<td>R150-16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.550 Schedule V add Brivaracetam</td>
<td>09/08/16</td>
<td>09/20/16</td>
<td>R149-16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.NEW Naloxone recordkeeping</td>
<td>10/13/16</td>
<td>10/25/16</td>
<td>R157-16</td>
<td>06/15/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td>09/27/17</td>
<td>10/31/17</td>
</tr>
<tr>
<td>453.460 Partial Filling of Prescriptions</td>
<td>03/01/17</td>
<td>03/21/17</td>
<td>R007-17</td>
<td>06/22/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td>01/30/18</td>
<td>02/27/18</td>
</tr>
<tr>
<td>10/31/17: LCB drafting changes from 10/19/17 WS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.510 Schedule I adding certain controlled substances</td>
<td>04/13/17</td>
<td>05/03/17</td>
<td>R011-17</td>
<td>06/29/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td>09/27/17</td>
<td>10/31/17</td>
</tr>
<tr>
<td>453.530 Schedule III HCG in non-humans</td>
<td>06/01/17</td>
<td>06/07/17</td>
<td>R013-17</td>
<td>06/14/17</td>
<td>08/02/17</td>
<td>09/07/17</td>
<td>09/27/17</td>
<td>10/31/17</td>
</tr>
<tr>
<td>453.440 DEA/ICD-10 Requirements</td>
<td>07/20/17</td>
<td>07/28/17</td>
<td>R046-17</td>
<td>09/05/17</td>
<td>11/01/17</td>
<td>12/06/17</td>
<td>12/13/17</td>
<td>02/27/18</td>
</tr>
<tr>
<td>639.926 Days Supply/Schedule V Reporting</td>
<td>07/20/17</td>
<td>07/28/17</td>
<td>R045-17</td>
<td>09/05/17</td>
<td>11/01/17</td>
<td>12/06/17</td>
<td>12/13/17</td>
<td>02/27/18</td>
</tr>
<tr>
<td>639 Veterinarians dispensing through consignment</td>
<td>09/07/17</td>
<td>12/12/17</td>
<td>R146-17</td>
<td>02/01/18</td>
<td>02/01/18</td>
<td>03/07/18</td>
<td>04/05/18</td>
<td></td>
</tr>
<tr>
<td>Regulation Number and Topic</td>
<td>Workshop Propose To Bd</td>
<td>30 Days To LCB W/Letter</td>
<td>LCB R0 Number Issued</td>
<td>LCB Return Date</td>
<td>30 Days Post Public Hearing</td>
<td>Public Hearing Meeting Date</td>
<td>To LCB Final W/ Cov./Info</td>
<td>Secretary of State File Date</td>
</tr>
<tr>
<td>----------------------------------------------------------------</td>
<td>------------------------</td>
<td>--------------------------</td>
<td>----------------------</td>
<td>-----------------</td>
<td>-----------------------------</td>
<td>----------------------------</td>
<td>-------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>639.010 Definition of Designated Agent</td>
<td>12/06/17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>639.670 USP 800</td>
<td>10/19/17</td>
<td>Close – Adopting USP 800</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>639.879 APRN Dispensing</td>
<td>10/19/17</td>
<td>11/02/17</td>
<td>R132-17</td>
<td>12/01/17</td>
<td></td>
<td>03/07/18</td>
<td>03/28/18</td>
<td></td>
</tr>
<tr>
<td>639 NEW Prescription Readers</td>
<td>10/19/17</td>
<td>11/02/17</td>
<td>R131-17</td>
<td>12/05/17</td>
<td>01/24/18</td>
<td>03/07/18</td>
<td>03/28/18</td>
<td></td>
</tr>
<tr>
<td>639 PMP Registration/Access</td>
<td>01/11/18</td>
<td>01/12/18</td>
<td>R013-18</td>
<td>04/30/18</td>
<td>05/03/18</td>
<td>06/07/18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>639 Show Cause</td>
<td>01/11/18</td>
<td>01/12/18</td>
<td>R014-18</td>
<td>02/27/18</td>
<td>03/13/18</td>
<td>04/12/18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>639.742 Vet Dispensing</td>
<td>01/11/18</td>
<td>01/12/18</td>
<td>R015-18</td>
<td>03/09/18</td>
<td>03/13/18</td>
<td>04/12/18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>639.220 Schedule of Fees</td>
<td>03/07/18</td>
<td>03/13/18</td>
<td>R047-18</td>
<td>04/17/18</td>
<td>05/08/18</td>
<td>06/07/18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>639.NEW Dispensing of CS in conformance with AB 474</td>
<td>03/07/18</td>
<td>03/15/18</td>
<td>R048-18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453.510 Schedule I – Adding New Substances (Fentanyl)</td>
<td>03/07/18</td>
<td>03/15/18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TEMPORARY LICENSES
(Issued since last board meeting)

Pipeline
  Jamie Beever

Mesa View Regional Hospital
  David Burchett

Renown
  Mikayla Rageth

Walgreens
  Payvand Hadjian
Important Product Information

BD Insulin Syringes

April 2018

For the Attention of:

Compounders, including 503B Outsourcing Facilities and Pharmacies
American Academy of Ophthalmology, American Society of Retina Specialists

Description of the problem and health hazard:

BD has become aware that its insulin syringes are being used for intraocular injections. Adverse events associated with “floaters” have been reported when insulin syringes are used for intraocular injections.

BD insulin syringes are intended for subcutaneous injection of insulin and have only been tested and validated for this intended use. These insulin syringes are safe and effective when used as intended.

Contact Information

If you have questions please contact us at 1-800 BD Cares (800-232-2737) between 8 AM and 5 PM ET Monday through Friday.

Please complete the attached acknowledgement form to confirm your receipt of this communication.

BD has informed the U.S. Food and Drug Administration of this safety alert. Any adverse health consequences experienced may be reported to the FDA’s MedWatch Adverse Event Reporting program.

- Web: MedWatch website at www.fda.gov/medwatch
- Phone: 1-800-FDA-1088 (1-800-332-1088)
- Mail: MedWatch, HF-2, FDA, 5600 Fisher’s Lane, Rockville, MD 20852-9787

BD is committed to advancing the world of health. Our primary objectives are patient and user safety. We thank you in advance for helping us to assure patient safety by using the insulin syringes only for their intended use.

Sincerely,

Laurence J. Hirsch, MD
VP Global Medical Affairs
BD Medical – Diabetes Care

Gail Griffiths
Sr. Director Regulatory Compliance
BD – US Region
NEVADA STATE BOARD OF PHARMACY

ACTIVITIES REPORT

APRIL 11-12, 2018 BOARD MEETING HELD IN LAS VEGAS, NEVADA

This report is prepared and presented to keep interested legislators and others abreast of the activities of the Nevada State Board of Pharmacy. Following is a summary of the April 2018 Board meeting.

Licensing Activity:

- 6 licenses were granted for Out-of-State MDEG (Medical Devices, Equipment and Gases) companies and 1 granted for a Nevada MDEG company.
- 14 licenses were granted for Out-of-State pharmacies; pending receipt of a favorable inspection for all compounding pharmacies, and 1 license application for further information.
- 8 licenses were granted for Out-of-State wholesalers.
- 8 licenses were granted for Nevada pharmacies and 1 application pulled for further information.
- 2 licenses were granted for Out-of-State Outsourcing Facilities & 1 application was postponed.
- 3 licenses were renewed and 1 denied for pharmacists with disciplinary issues in other states.
- 1 license was denied for a pharmacy tech in training for testing positive for a schedule 1 substance.
- A progress report was offered by a revoked pharmacist, who was asked to continue with his internship prior to reapplying for his license reinstatement.
- 1 license was granted for a Physician’s Assistant with past regulatory issues.

Disciplinary Actions:

- Pharmacist NZ was revoked for creating, filling and sending a prescription out of state to her sister without authorization from a prescriber.
- Pharmacist DB was ordered a letter of reprimand; 2 extra hours of CE; and fined $1K for dispensing the wrong strength of phenobarbital resulting in seizure activity in a canine.
- Pharmacy WG was fined an administrative fee of $1500.
- Pharmacy Technician KR was revoked for diversion of controlled substances for self-administration.
- Physician CW’s stipulated agreement was denied by the Board and asked to be heard in July. Two of CW’s dispensing techs were revoked for dispensing without the physician’s authority.

Other Activity:

- The usual Board business reports were given, including recent and future speaking engagements; reports on national meetings; and collaboration with other state agencies.
- The Board discussed a petition for regulatory interpretation regarding the authority to possess and administer dangerous drugs.
- The NABP “blueprint” inspection process was discussed and moved forward for Nevada inspections.
Public Hearing:

A. **Amendment of Nevada Administrative Code Chapter 639 to add a new section thereto for the registration of veterinarians to dispense controlled substances or dangerous drugs.** Establishes the requirements for a licensed veterinarian to obtain a certificate of registration to dispense controlled substances or dangerous drugs; and revising the fees for a licensed veterinarian to dispense controlled substances or dangerous drugs. (LCB File No. R015-18)

B. **Amendment of Nevada Administrative Code Chapter 639 to add a new section thereto authorizing the State Board of Pharmacy to issue an order for a hearing to show cause.** Enacts the requirements for the issuance of an order to appear at a hearing to show cause to a respondent to fails to comply with an order imposing discipline. (LCB File No. R014-18)